Post of the Day...imo...other than the news!
Link back for Post
----------------------------------------
Posted by: choo choo trader Member Level Date: Friday, January 29, 2010 1:42:13 PM
In reply to: None Post # of 3268 Send a link
via email Share on Facebook Tweet this post
Hi All,
I haven't posted in a while,just waiting on things to start happening. I know the following article has already been posted by another poster,but some points to consider.
1. I think the current rally is do to HDC speaking at the recent FSX Conference along with the following article by BioMedReports(they have a huge following,me included).
2. The article relates to the speculation on news surrounding the company's new gene-based molecular diagnostic test for prostate cancer,which has successfully completed it’s Phase III double-blind clinical trial and is now ready for commercialization by Clarient. I think we as investors had more or less placed this one on the back burner.
3. The article doesn't mention anything about the Quest and Abbott deals.
4. BioMedReports will be releasing a more in depth report on Monday which will surely at least partially focus on the deals with Quest and Abbott.
5. I think Monday will be a good day for all of us longs.
Written by BioMedReports.Com
Friday, 29 January 2010 06:45
Yesterday, this nationwide network of independent broker/dealers, investment bankers other dealers heard a presentation at the FSX Conference which is taking place at the Ritz Carlton Hotel in Dallas.
Health Discovery Corporation's (HDVY.OB) presentation there went very well and apparently, someone feels now may finally be HDVY's time. Shares of the company have started trading higher and there is some speculation that big news may be on the horizon for the company.
We are preparing a report for Monday,
but speculation centers on news surrounding the company's new gene-based molecular diagnostic test for prostate cancer - which has successfully completed it’s Phase III double-blind clinical trial and is now ready for commercialization.
The new prostate cancer test will be performed at Clarient’s Clinical Laboratory in Aliso Viejo, CA. HDC will receive 30% royalty on each test performed, according to the company's website.
You may or may not be aware that HDVY was the company that developed the technology that sent Vermillion's (VMRL.PQ) shares soaring.
The market potential for Vermillion's test pales in comparison to the potential revenues and market for this new prostate cancer test.
Stay tuned for our report, plus news and developments from the company in the coming days and weeks ahead. HDVY could turn out to be one of the bigger biotech plays of the year.
Disclosure: No Positions
BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section
